ArticleScientific reports2016
A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma.Nature communications · 2025Article
- Knowledge mapping and current trends of global research on CRISPR in the field of cancer.Frontiers in cell and developmental biology · 2023Article
- Review
- In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis.Molecular oncology · 2022Article
- An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.Cancer research · 2022Article
- Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR-Cas9 screen.EMBO reports · 2022Article
- Applying CRISPR Screen in Diabetes Research.Diabetes · 2021Review
- Improving T cell therapy:Precision clinical medicine · 2021Article
- Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science.Annual review of biomedical engineering · 2021Article
- Functional Genomic Screening During Somatic Cell Reprogramming Identifies DKK3 as a Roadblock of Organ Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation.Cancers · 2021Article
- Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications.Frontiers in genetics · 2021Review
- Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.Frontiers in immunology · 2021Review
- The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.Journal of cellular and molecular medicine · 2020Review
- Article
- Synthetic Biology Speeds Up Drug Target Discovery.Frontiers in pharmacology · 2020Review
- Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous KrasScientific reports · 2019Article
- CRISPR-Cas: a tool for cancer research and therapeutics.Nature reviews. Clinical oncology · 2019Review
- Development and Significance of Mouse Models in Lymphoma Research.Current hematologic malignancy reports · 2019Review
- CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics.Cancer cell international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An enormous amount of tumor sequencing data has been generated through large scale sequencing efforts. The functional consequences of the majority of mutations identified by such projects remain an open, unexplored question. This problem is particularly complicated in the case of rare mutations where frequency of occurrence alone or prediction of functional consequences are insufficient to distinguish driver from passenger or bystander mutations. We combine genome editing technology with a powerful mouse cancer model to uncover previously unsuspected rare oncogenic mutations in Burkitt's lymphoma. We identify two candidate tumor suppressors whose loss cooperate with MYC over-expression to accelerate lymphomagenesis. Our results highlight the utility of in vivo CRISPR/Cas9 screens combined with powerful mouse models to identify and validate rare oncogenic modifier events from tumor mutational data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.